NervGen Pharma Corp. (NGEN) - Net Assets
Based on the latest financial reports, NervGen Pharma Corp. (NGEN) has net assets worth $17.31 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($90.34 Million) and total liabilities ($73.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NervGen Pharma Corp. (NGEN) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $17.31 Million |
| % of Total Assets | 19.16% |
| Annual Growth Rate | 4.79% |
| 5-Year Change | -79.48% |
| 10-Year Change | N/A |
| Growth Volatility | 100.45 |
NervGen Pharma Corp. - Net Assets Trend (2018–2025)
This chart illustrates how NervGen Pharma Corp.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see NervGen Pharma Corp. market cap and net worth.
Annual Net Assets for NervGen Pharma Corp. (2018–2025)
The table below shows the annual net assets of NervGen Pharma Corp. from 2018 to 2025. Also explore NervGen Pharma Corp. equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.48 Million | +35.03% |
| 2024-12-31 | $2.57 Million | +228.15% |
| 2023-12-31 | $-2.01 Million | -115.06% |
| 2022-12-31 | $13.34 Million | -21.26% |
| 2021-12-31 | $16.95 Million | +185.60% |
| 2020-12-31 | $5.93 Million | -1.12% |
| 2019-12-31 | $6.00 Million | +139.43% |
| 2018-12-31 | $2.51 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NervGen Pharma Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14539756600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $103.00 Million | 2962.36% |
| Other Components | $47.24 Million | 1358.71% |
| Total Equity | $3.48 Million | 100.00% |
NervGen Pharma Corp. Competitors by Market Cap
The table below lists competitors of NervGen Pharma Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Transimex Saigon Corp
VN:TMS
|
$229.03 Million |
|
Lingnan Landscape Co Ltd
SHE:002717
|
$229.07 Million |
|
Hawthorn Bancshares Inc
NASDAQ:HWBK
|
$229.07 Million |
|
TSS, Inc. Common Stock
NASDAQ:TSSI
|
$229.08 Million |
|
Chongqing Machinery & Electric Co. Ltd
F:CE3
|
$228.95 Million |
|
Hi-Lai Foods Co Ltd
TWO:1268
|
$228.81 Million |
|
Kalyani Investment Company Limited
NSE:KICL
|
$228.80 Million |
|
Squirrel Media SA
MC:SQRL
|
$228.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NervGen Pharma Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,574,877 to 3,476,926, a change of 902,049 (35.0%).
- Net loss of 44,117,305 reduced equity.
- New share issuances of 16,884,659 increased equity.
- Other comprehensive income decreased equity by 23,619,988.
- Other factors increased equity by 51,754,683.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-44.12 Million | -1268.86% |
| Share Issuances | $16.88 Million | +485.62% |
| Other Comprehensive Income | $-23.62 Million | -679.34% |
| Other Changes | $51.75 Million | +1488.52% |
| Total Change | $- | 35.03% |
Book Value vs Market Value Analysis
This analysis compares NervGen Pharma Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 44.52x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 23.23x to 44.52x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.09 | $2.14 | x |
| 2019-12-31 | $0.23 | $2.14 | x |
| 2020-12-31 | $0.18 | $2.14 | x |
| 2021-12-31 | $0.43 | $2.14 | x |
| 2022-12-31 | $0.25 | $2.14 | x |
| 2023-12-31 | $-0.03 | $2.14 | x |
| 2024-12-31 | $0.04 | $2.14 | x |
| 2025-12-31 | $0.05 | $2.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NervGen Pharma Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1268.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 6.68x
- Recent ROE (-1268.86%) is below the historical average (-355.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -54.03% | 0.00% | 0.00x | 1.23x | $-1.60 Million |
| 2019 | -167.18% | 0.00% | 0.00x | 1.16x | $-10.63 Million |
| 2020 | -188.95% | 0.00% | 0.00x | 1.13x | $-11.80 Million |
| 2021 | -75.67% | 0.00% | 0.00x | 1.06x | $-14.52 Million |
| 2022 | -153.94% | 0.00% | 0.00x | 1.77x | $-21.87 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.18 Million |
| 2024 | -931.69% | 0.00% | 0.00x | 7.56x | $-24.25 Million |
| 2025 | -1268.86% | 0.00% | 0.00x | 6.68x | $-44.46 Million |
Industry Comparison
This section compares NervGen Pharma Corp.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NervGen Pharma Corp. (NGEN) | $17.31 Million | -54.03% | 4.22x | $229.02 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About NervGen Pharma Corp.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's… Read more